CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.…
CeriBell (CBLL) Climbed, What Is Behind The Fresh Attention?
CeriBell (NASDAQ: CBLL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 327 employees.
The shares were at 27.39 USD on 20 November 2026, up 100.7% over 52 weeks. Its 52-week range is 13.52 USD to 28.89 USD: the price is 5.2% below the high and 102.6% above the low.
Its market capitalisation is 1.06B USD.
CeriBell reports return on equity of -34.4%, an operating margin of -69.8% and revenue up 29.9% year over year.
It holds more cash than debt, a net cash position of 95.82M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 31.57 USD is 15.3% above the current price. The next earnings report is expected on 23 February 2027.